Golimumab in Children with Chronic Recurrent Multifocal Osteomyelitis: A Case Series and Review of the Literature
CONCLUSION: In our experience, golimumab has been shown to be a safe and effective therapy for CRMO and demonstrated improvement in paradoxical psoriasis in many patients. Longer follow-up periods would be helpful to develop longer term outcomes data for patients with CRMO and overall paradoxical psoriasis risk.PMID:37479948 | DOI:10.1007/s40272-023-00581-y (Source: Paediatric Drugs)
Source: Paediatric Drugs - July 21, 2023 Category: Pediatrics Authors: Claire Yang Natalie Rosenwasser Xing Wang Zheng Xu Joshua Scheck Markus D Boos Deepti Gupta Heather A Brandling-Bennet Robert Sidbury Ramesh S Iyer Yongdong Zhao Source Type: research
A Review of Histamine-2 Receptor Antagonist and Proton Pump Inhibitor Therapy for Gastroesophageal Reflux Disease in Neonates and Infants
Paediatr Drugs. 2023 Jul 17. doi: 10.1007/s40272-023-00580-z. Online ahead of print.ABSTRACTProton pump inhibitors (PPI) and histamine-2 receptor antagonists (H2RA) are commonly used medications in neonates and infants for the treatment of gastroesophageal reflux disease (GERD), especially in neonatal intensive care units (NICUs). A literature review was conducted to evaluate the efficacy and safety of histamine-2 receptor antagonists (H2RAs) and proton pump inhibitors (PPIs) in preterm neonates, term neonates, and infants. A total of 27 studies were included in this review. Antacid medications in studies have consistently...
Source: Paediatric Drugs - July 17, 2023 Category: Pediatrics Authors: Jason Tan Sonia Jeffries Roxane Carr Source Type: research
A Review of Histamine-2 Receptor Antagonist and Proton Pump Inhibitor Therapy for Gastroesophageal Reflux Disease in Neonates and Infants
Paediatr Drugs. 2023 Jul 17. doi: 10.1007/s40272-023-00580-z. Online ahead of print.ABSTRACTProton pump inhibitors (PPI) and histamine-2 receptor antagonists (H2RA) are commonly used medications in neonates and infants for the treatment of gastroesophageal reflux disease (GERD), especially in neonatal intensive care units (NICUs). A literature review was conducted to evaluate the efficacy and safety of histamine-2 receptor antagonists (H2RAs) and proton pump inhibitors (PPIs) in preterm neonates, term neonates, and infants. A total of 27 studies were included in this review. Antacid medications in studies have consistently...
Source: Paediatric Drugs - July 17, 2023 Category: Pediatrics Authors: Jason Tan Sonia Jeffries Roxane Carr Source Type: research
A Review of Histamine-2 Receptor Antagonist and Proton Pump Inhibitor Therapy for Gastroesophageal Reflux Disease in Neonates and Infants
Paediatr Drugs. 2023 Jul 17. doi: 10.1007/s40272-023-00580-z. Online ahead of print.ABSTRACTProton pump inhibitors (PPI) and histamine-2 receptor antagonists (H2RA) are commonly used medications in neonates and infants for the treatment of gastroesophageal reflux disease (GERD), especially in neonatal intensive care units (NICUs). A literature review was conducted to evaluate the efficacy and safety of histamine-2 receptor antagonists (H2RAs) and proton pump inhibitors (PPIs) in preterm neonates, term neonates, and infants. A total of 27 studies were included in this review. Antacid medications in studies have consistently...
Source: Paediatric Drugs - July 17, 2023 Category: Pediatrics Authors: Jason Tan Sonia Jeffries Roxane Carr Source Type: research
A Review of Histamine-2 Receptor Antagonist and Proton Pump Inhibitor Therapy for Gastroesophageal Reflux Disease in Neonates and Infants
Paediatr Drugs. 2023 Jul 17. doi: 10.1007/s40272-023-00580-z. Online ahead of print.ABSTRACTProton pump inhibitors (PPI) and histamine-2 receptor antagonists (H2RA) are commonly used medications in neonates and infants for the treatment of gastroesophageal reflux disease (GERD), especially in neonatal intensive care units (NICUs). A literature review was conducted to evaluate the efficacy and safety of histamine-2 receptor antagonists (H2RAs) and proton pump inhibitors (PPIs) in preterm neonates, term neonates, and infants. A total of 27 studies were included in this review. Antacid medications in studies have consistently...
Source: Paediatric Drugs - July 17, 2023 Category: Pediatrics Authors: Jason Tan Sonia Jeffries Roxane Carr Source Type: research
Pharmacokinetics of Commonly Used Antimicrobials in Critically Ill Pediatric Patients During Extracorporeal Membrane Oxygenation: A Systematic Review
CONCLUSION: Limited data exists on the PK/PD of antimicrobials during ECMO therapy in the pediatric population. Rigorously designed population PK studies are required to establish empiric dosing guidelines for antimicrobials in patients requiring this therapeutic modality. The use of therapeutic drug monitoring for antimicrobials in pediatric patients on ECMO should be encouraged to optimize dosing.TRIAL REGISTRY: PROSPERO registration number: CRD42018099992 (Registered: July 24th 2018).PMID:37450191 | DOI:10.1007/s40272-023-00582-x (Source: Paediatric Drugs)
Source: Paediatric Drugs - July 14, 2023 Category: Pediatrics Authors: Marc-Alexandre Duceppe Salmaan Kanji Anh Thu Do Ni Ruo Yiorgos Alexandros Cavayas Martin Albert Maxime Robert-Halabi Samara Zavalkoff Laura Benichou Gordan Samoukovic David R Williamson Source Type: research
Pharmacokinetics of Commonly Used Antimicrobials in Critically Ill Pediatric Patients During Extracorporeal Membrane Oxygenation: A Systematic Review
CONCLUSION: Limited data exists on the PK/PD of antimicrobials during ECMO therapy in the pediatric population. Rigorously designed population PK studies are required to establish empiric dosing guidelines for antimicrobials in patients requiring this therapeutic modality. The use of therapeutic drug monitoring for antimicrobials in pediatric patients on ECMO should be encouraged to optimize dosing.TRIAL REGISTRY: PROSPERO registration number: CRD42018099992 (Registered: July 24th 2018).PMID:37450191 | DOI:10.1007/s40272-023-00582-x (Source: Paediatric Drugs)
Source: Paediatric Drugs - July 14, 2023 Category: Pediatrics Authors: Marc-Alexandre Duceppe Salmaan Kanji Anh Thu Do Ni Ruo Yiorgos Alexandros Cavayas Martin Albert Maxime Robert-Halabi Samara Zavalkoff Laura Benichou Gordan Samoukovic David R Williamson Source Type: research
Pharmacokinetics of Commonly Used Antimicrobials in Critically Ill Pediatric Patients During Extracorporeal Membrane Oxygenation: A Systematic Review
CONCLUSION: Limited data exists on the PK/PD of antimicrobials during ECMO therapy in the pediatric population. Rigorously designed population PK studies are required to establish empiric dosing guidelines for antimicrobials in patients requiring this therapeutic modality. The use of therapeutic drug monitoring for antimicrobials in pediatric patients on ECMO should be encouraged to optimize dosing.TRIAL REGISTRY: PROSPERO registration number: CRD42018099992 (Registered: July 24th 2018).PMID:37450191 | DOI:10.1007/s40272-023-00582-x (Source: Paediatric Drugs)
Source: Paediatric Drugs - July 14, 2023 Category: Pediatrics Authors: Marc-Alexandre Duceppe Salmaan Kanji Anh Thu Do Ni Ruo Yiorgos Alexandros Cavayas Martin Albert Maxime Robert-Halabi Samara Zavalkoff Laura Benichou Gordan Samoukovic David R Williamson Source Type: research
20 ‑Valent Pneumococcal Conjugate Vaccine: Pediatric First Approval
This article summarizes the milestones in the development of PCV20 leading to this first pediatric approval for active immunization for the prevention of IPD and otitis media caused by S. pneumoniae.PMID:37440125 | DOI:10.1007/s40272-023-00584-9 (Source: Paediatric Drugs)
Source: Paediatric Drugs - July 13, 2023 Category: Pediatrics Authors: Matt Shirley Source Type: research
20 ‑Valent Pneumococcal Conjugate Vaccine: Pediatric First Approval
This article summarizes the milestones in the development of PCV20 leading to this first pediatric approval for active immunization for the prevention of IPD and otitis media caused by S. pneumoniae.PMID:37440125 | DOI:10.1007/s40272-023-00584-9 (Source: Paediatric Drugs)
Source: Paediatric Drugs - July 13, 2023 Category: Pediatrics Authors: Matt Shirley Source Type: research
Management of Central Diabetes Insipidus in Disabled Children with Diluted Oral Desmopressin Lyophilisate Formulation Administered Through Nasogastric Tube: A Retrospective Case Series
CONCLUSIONS: Nasogastric administration of oral DDAVP lyophilised formulation was safe and effective in the treatment of CDI in disabled children in this small retrospective series.PMID:37326929 | DOI:10.1007/s40272-023-00578-7 (Source: Paediatric Drugs)
Source: Paediatric Drugs - June 16, 2023 Category: Pediatrics Authors: H üseyin Anıl Korkmaz Ved Bhushan Arya Ahmet G önüllü Fulya Co şkunol Behzat Ozkan Source Type: research
Management of Central Diabetes Insipidus in Disabled Children with Diluted Oral Desmopressin Lyophilisate Formulation Administered Through Nasogastric Tube: A Retrospective Case Series
CONCLUSIONS: Nasogastric administration of oral DDAVP lyophilised formulation was safe and effective in the treatment of CDI in disabled children in this small retrospective series.PMID:37326929 | DOI:10.1007/s40272-023-00578-7 (Source: Paediatric Drugs)
Source: Paediatric Drugs - June 16, 2023 Category: Pediatrics Authors: H üseyin Anıl Korkmaz Ved Bhushan Arya Ahmet G önüllü Fulya Co şkunol Behzat Ozkan Source Type: research
Management of Central Diabetes Insipidus in Disabled Children with Diluted Oral Desmopressin Lyophilisate Formulation Administered Through Nasogastric Tube: A Retrospective Case Series
CONCLUSIONS: Nasogastric administration of oral DDAVP lyophilised formulation was safe and effective in the treatment of CDI in disabled children in this small retrospective series.PMID:37326929 | DOI:10.1007/s40272-023-00578-7 (Source: Paediatric Drugs)
Source: Paediatric Drugs - June 16, 2023 Category: Pediatrics Authors: H üseyin Anıl Korkmaz Ved Bhushan Arya Ahmet G önüllü Fulya Co şkunol Behzat Ozkan Source Type: research
Management of Central Diabetes Insipidus in Disabled Children with Diluted Oral Desmopressin Lyophilisate Formulation Administered Through Nasogastric Tube: A Retrospective Case Series
CONCLUSIONS: Nasogastric administration of oral DDAVP lyophilised formulation was safe and effective in the treatment of CDI in disabled children in this small retrospective series.PMID:37326929 | DOI:10.1007/s40272-023-00578-7 (Source: Paediatric Drugs)
Source: Paediatric Drugs - June 16, 2023 Category: Pediatrics Authors: H üseyin Anıl Korkmaz Ved Bhushan Arya Ahmet G önüllü Fulya Co şkunol Behzat Ozkan Source Type: research
Management of Central Diabetes Insipidus in Disabled Children with Diluted Oral Desmopressin Lyophilisate Formulation Administered Through Nasogastric Tube: A Retrospective Case Series
CONCLUSIONS: Nasogastric administration of oral DDAVP lyophilised formulation was safe and effective in the treatment of CDI in disabled children in this small retrospective series.PMID:37326929 | DOI:10.1007/s40272-023-00578-7 (Source: Paediatric Drugs)
Source: Paediatric Drugs - June 16, 2023 Category: Pediatrics Authors: H üseyin Anıl Korkmaz Ved Bhushan Arya Ahmet G önüllü Fulya Co şkunol Behzat Ozkan Source Type: research
